Consun Pharma
Consun Pharma, officially known as China Consun Pharmaceutical Group, is a prominent player in the pharmaceutical industry, headquartered in China (CN). Established in 1995, the company has made significant strides in the development and manufacturing of high-quality pharmaceutical products, primarily focusing on prescription medications and over-the-counter solutions.
With a strong operational presence across Asia and expanding into international markets, Consun Pharma is recognised for its commitment to innovation and quality. The company’s core offerings include a diverse range of therapeutic drugs, particularly in the fields of cardiovascular health and anti-infectives, distinguished by their efficacy and safety profiles.
Notably, Consun Pharma has achieved several milestones, including certifications from international regulatory bodies, which solidify its market position as a trusted provider in the global pharmaceutical landscape.
-17 vs industry average
Consun Pharma’s score of 21 is lower than 42% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Consun Pharma?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Emissions trajectory 2020 – 2025
Reported emissions
Scope 3 accounts for ••• of total emissions.
Consun Pharma's reported carbon emissions
In 2022, Consun Pharma reported total carbon emissions of approximately 72,057,200 kg CO2e, comprising 53,214,680 kg CO2e from Scope 1 and 18,842,520 kg CO2e from Scope 2 emissions. The company has set a significant commitment to reduce its absolute Scope 1 and 2 emissions by at least 42% by 2030, using 2021 as the baseline year. This ambitious target reflects Consun Pharma's dedication to addressing climate change and reducing its carbon footprint. The emissions data is not cascaded from any parent organization, indicating that these figures are independently reported by Consun Pharmaceutical Group Limited. As of now, there is no disclosed data for Scope 3 emissions, which typically encompass indirect emissions from the supply chain and product use. Overall, Consun Pharma's climate commitments and reduction targets align with industry standards, showcasing its proactive approach to sustainability and environmental responsibility.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Consun Pharma’s Climate Goals (2030 & 2050)
2 goals2030
42% reduction in Scope 1
Asker has committed to reducing the company’s absolute Scope 1 and 2 emissions, by at least 42 per cent by 2030, with 2021 as the base year.
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
See all 2 climate goals
Already have an account? Sign in now
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Emissions comparison with industry peers
View similar organisations
Consun Pharma
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project